Dementia Support Line
Research and innovation
Read the full version of our Trustees' Annual Report & Financial Statements 2022/23
Investing in research is vital to improving lives
£0 invested
£12.2m was invested in dementia research throughout 2022/23.
0 new grants
25 new grants were funded in total, supporting early career researchers and fuelling innovation in dementia treatment, diagnosis and care.
Exploring new treatments that could slow Alzheimer’s disease progression
In November 2022, the results of a phase three trial for lecanemab showed it slowed cognitive decline in people with early-stage Alzheimer’s disease by 27% and improved carer quality of life by up to 56%.
Our research led to the first clinical trials for targeted dementia treatments such as lecanemab. Today there are 143 drugs being trialled in people with Alzheimer’s disease.
Leading innovation in dementia care and support technology
The Longitude Prize on Dementia is aimed at developing breakthrough technologies co-created alongside people living with early-stage dementia. We jointly funded the prize with Innovate UK (and delivered in partnership with Challenge
Works).
The Longitude Prize on Dementia will provide £4.34 million to help develop and test new solutions – consisting of £3.34 million in seed funding and £1million to the grand prize winner.